U.S. Markets closed

Global Neurodiagnostics Industry Outlook, 2019-2024: Opportunities Presented by Increasing Application in Clinical Trials, and Emerging Markets

DUBLIN, Jan. 10, 2020 /PRNewswire/ -- The "Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global neurodiagnostics market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%.

The demand for neurodiagnostic products is expected to grow due to the increasing prevalence of neurological disorders & diseases. The neurodiagnostics market is segmented on product, condition, end-user, and region.

The hospitals & surgical centers segment accounted for the largest share of the neurodiagnostics market by end-user in 2018.

Based on end-user, the neurodiagnostics market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes. In 2018, hospitals & surgical centers accounted for the largest share of the neurodiagnostics market due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.

The neurodegenerative diseases segment accounted for the largest share of the neurodiagnostics market by condition in 2018.

The neurodiagnostics market, by condition, is segmented into neurodegenerative diseases, epilepsy, stroke, headache disorders, sleep disorders, and other conditions. In 2019, the neurodegenerative diseases segment is expected to account for the largest share of the neurodiagnostics market due to the increasing incidence of traumatic brain injuries, dementia, Parkinson's disease, and Huntington's disease, and the growing number of neurological examinations for the diagnosis of these conditions.

North America accounted for the largest share of the neurodiagnostics market in 2018.

North America accounted for the largest share of the neurodiagnostics market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, full availability of advanced neurodiagnostic tools, and the large number of neurodiagnostic devices manufacturing companies that have an established base or are headquartered in the US.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Market Overview
4.2 Neurodiagnostics Market, By Product, 2019 Vs. 2024
4.3 Market Share, By End User and Region (2019)
4.4 Market, By Condition, 2019 Vs. 2024 (USD Million)
4.5 Market, By Country

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Neurological Diseases & Disorders
5.2.1.2 Technological Advancements
5.2.1.3 Growing Patient Emphasis on Effective and Early Disease Diagnosis
5.2.1.4 Increasing Number of Diagnostic Centers & Hospitals
5.2.1.5 Advances in Genomics and Proteomics for the Diagnosis of Neurodegenerative Disorders
5.2.2 Restraints
5.2.2.1 High Cost of Neurodiagnostic Devices
5.2.2.2 Growing Adoption of Refurbished Neurodiagnostic Systems
5.2.3 Opportunities
5.2.3.1 Increasing Application in Clinical Trials
5.2.3.2 Emerging Markets
5.2.4 Challenges
5.2.4.1 Dearth of Skilled Surgeons

6 Neurodiagnostics Market, By Product
6.1 Introduction
6.2 Diagnostic Imaging Systems
6.2.1 Growing Number of Diagnostic Laboratories & Imaging Centers to Drive the Adoption of Diagnostic Imaging Systems
6.2.1.1 MRI Systems
6.2.1.2 EEG Systems
6.2.1.3 CT Scanners
6.2.1.4 PET Scanners
6.2.1.5 EMG Devices
6.2.1.6 Ultrasound Imaging Systems
6.2.1.7 MEG Devices
6.2.1.8 Angiography Systems
6.2.1.9 Other Diagnostic Imaging Systems
6.3 Clinical Diagnostic Instruments
6.3.1 Increasing Public-Private Investments are Supporting the Growth of This Market Segment
6.3.1.1 PCR Instruments
6.3.1.2 NGS Instruments
6.3.1.3 Sanger Sequencers
6.3.1.4 Other Clinical Diagnostic Instruments
6.4 Reagents & Consumables
6.4.1 High Consumption of Reagents in Various Routine Assays & Techniques is Driving the Growth of This Segment
6.4.1.1 Media & Sera
6.4.1.2 Antibodies
6.4.1.3 Buffers
6.4.1.4 Solvents
6.4.1.5 Enzymes, Proteins, & Peptides
6.4.1.6 Probes
6.4.1.7 Other Reagents & Consumables

7 Neurodiagnostics Market, By Condition
7.1 Introduction
7.2 Neurodegenerative Diseases
7.2.1 Growing Number of Neurological Examinations is Supporting the Growth of This Segment
7.3 Stroke
7.3.1 Growing Awareness About Strokes & Its Treatment Options in the Market are Supporting Market Growth
7.4 Epilepsy
7.4.1 Favorable Government Initiatives Have Resulted in the Increased Adoption of Neurodiagnostic Products
7.5 Headache Disorders
7.5.1 Increasing Incidence of Migraines & Tension Headaches to Support Market Growth
7.6 Sleep Disorders
7.6.1 Increasing Stress & Unhealthy Lifestyles are Supporting the Growth of This Market Segment

8 Neurodiagnostics Market, By End User
8.1 Introduction
8.2 Hospitals & Surgical Centers
8.2.1 Hospitals & Surgical Centers are the Major End Users of Neurodiagnostic Devices Owing to Their High Purchasing Power to Buy Expensive Equipment
8.3 Diagnostic Laboratories & Imaging Centers
8.3.1 Growing Number of Private Imaging Centers Supports the Growth of This End-User Segment
8.4 Neurology Centers
8.4.1 Lower Costs and Shorter Waiting Periods Compared to Hospitals to Drive Market Growth
8.5 Ambulatory Care Centers
8.5.1 High-Quality and Lower-Cost Services Offered By Ambulatory Care Centers to Drive Market Growth
8.6 Research Laboratories & Academic Institutes
8.6.1 Budgetary Limitations Faced By Small Research Laboratories & Academic Institutes Will Restrain Market Growth

9 Neurodiagnostics Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 US Dominates the Market Due to the Increased Adoption of High-End Neurodiagnostic Systems
9.2.2 Canada
9.2.2.1 Favorable Environment for R&D in the Field of Neurosciences is Driving Market Growth
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Commands the Largest Share of the Neurodiagnostics Market in Europe
9.3.2 UK
9.3.2.1 Market Growth in the UK is Mainly Driven By the Increasing Incidence of Neurodegenerative Diseases
9.3.3 France
9.3.3.1 Increasing Healthcare Expenditure Coupled With the High-End Medical Infrastructure Will Drive Demand for Neurodiagnostic Devices
9.3.4 Italy
9.3.4.1 Ongoing Economic Crisis in the Country and Rising Government Pressure to Reduce Healthcare Costs May Slow Market Growth
9.3.5 Spain
9.3.5.1 Increased Cost Burden on the State-Run Health Insurance System Will Hinder Market Growth
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Favorable Reimbursement and Growing Neurological Disorder Patients Have Propelled Market Growth in Japan
9.4.2 China
9.4.2.1 Government Initiatives to Modernize Healthcare Facilities and the Rising Geriatric Population Will Drive Market Growth
9.4.3 India
9.4.3.1 Low Entry Barriers Have Made India a Prominent Market to Invest In
9.4.4 Australia
9.4.4.1 Technology Advancements and Improving Healthcare Infrastructure Will Drive the Market in Australia
9.4.5 South Korea
9.4.5.1 Rising Healthcare Spending and Medical Coverage for Neurological Disease Treatment Will Propel the Market Growth
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Inadequate Accessibility to Healthcare has Driven the Government to Undertake Corrective Measures
9.5.2 Mexico
9.5.2.1 Mexico is a Prominent Medical Tourism Hub for US Patients
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Infrastructural Development and Growing Healthcare Expenditure Will Contribute to Market Growth in the MEA

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Key Product Launches
10.3.2 Key Expansions
10.3.3 Key Acquisitions
10.3.4 Key Partnerships, Agreements, and Collaborations
10.4 Competitive Leadership Mapping
10.4.1 Visionary Leaders
10.4.2 Innovators
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies

11 Company Profiles
11.1 GE Healthcare
11.2 Philips Healthcare
11.3 Siemens Healthineers
11.4 Hitachi, Ltd.
11.5 Canon, Inc.
11.6 Lifelines Neuro Company, LLC
11.7 Natus Medical Incorporated
11.8 F. Hoffmann-La Roche AG
11.9 FUJIFILM Holdings Corporation
11.10 Mitsar Co. Ltd.
11.11 Advanced Brain Monitoring, Inc.
11.12 Thermo Fisher Scientific, Inc.
11.13 Bio-Rad Laboratories
11.14 QIAGEN N.V.
11.15 Nihon Kohden Corporation
11.16 Other Companies
11.16.1 ANT Neuro
11.16.2 Fonar Corporation
11.16.3 Fujirebio (A Part of Miraca Group)
11.16.4 DRG Instruments GmbH
11.16.5 Tecan Trading AG

For more information about this report visit https://www.researchandmarkets.com/r/cq0afl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision

View original content:http://www.prnewswire.com/news-releases/global-neurodiagnostics-industry-outlook-2019-2024-opportunities-presented-by-increasing-application-in-clinical-trials-and-emerging-markets-300984904.html

SOURCE Research and Markets